Cagrilintide on its own: what the clinical studies have tested

TL;DR

• Researchers have studied cagrilintide alone and with semaglutide, but the strongest standalone evidence concerns body-weight change in selected adults rather than broad health outcomes.¹
• A large phase 3 trial included 302 adults in a cagrilintide-only group, although its main comparison focused on the combination rather than cagrilintide alone.²
• A pooled analysis found greater average weight reduction with cagrilintide alone than placebo, but it combined only a few trials.³
• Small kidney and liver studies examined drug handling and short-term tolerability after one administration, not long-term weight or disease outcomes.⁴

For Filipino readers who encounter cagrilintide online, one question matters: what have researchers tested when they used it alone? Published evidence covers weight-focused trials, small drug-handling studies, and early work on how it may act.¹ Each study type answers a different question and has clear limits.¹ Keeping those categories separate makes the evidence easier to read.

What cagrilintide is, and why “on its own” matters

Cagrilintide is a long-acting analogue of amylin, a hormone involved in satiation and food-intake regulation.¹ Structural laboratory research describes it as an agonist at amylin and calcitonin receptors.⁵ That receptor profile differs from semaglutide, which acts through the GLP-1 receptor.⁵ Researchers have therefore studied cagrilintide both alone and in combination with semaglutide.¹

Those bodies of evidence are not interchangeable.² A combination result cannot show how much came from cagrilintide alone.² The cleanest standalone evidence comes from trial groups assigned only cagrilintide or placebo.² Reviews can summarize those groups, while laboratory and animal studies can explore possible mechanisms.³ They still cannot replace direct human clinical outcomes.⁶

Cagrilintide appears below only as a neutral catalog reference.

The main standalone question was body-weight change

The large REDEFINE 1 trial enrolled 3,417 adults without diabetes.² They had obesity or overweight with a related condition.² Everyone also received a lifestyle intervention.² The study did not isolate the study compound from that shared background.² Researchers randomly assigned 302 participants to cagrilintide alone and 705 to placebo.² Other groups received semaglutide alone or the cagrilintide-semaglutide combination.²

The trial ran for 68 weeks and tracked relative body-weight change and safety.² Its main comparisons, however, centered on the combination against placebo.² The abstract confirms that a standalone arm existed. It does not give a numerical weight result for that arm.² The paper is relevant, but its abstract cannot support a precise standalone percentage.²

What pooled human evidence says

A 2026 systematic review and meta-analysis pooled four randomized trials with 5,023 participants.³ It assessed cagrilintide-based approaches in adults with overweight or obesity.³ For cagrilintide alone, the pooled difference in percent body weight versus placebo was minus 6.08 percentage points.³ The reported 95% confidence interval ranged from minus 8.02 to minus 4.14 percentage points.³

That figure compares randomized groups. It is not an individual forecast.³ It also reflects the studies and analysis choices included by the review authors.³ The review pooled only four trials across standalone and combination evidence, so the evidence base remained small.³ The same analysis found no statistically significant glycemic effect for cagrilintide alone.³ Its authors described modest blood-pressure changes, but a pooled summary cannot establish wider clinical benefit.³

Safety findings need the same context

The pooled review found overall adverse events were more frequent with active cagrilintide-based treatment than placebo.⁷ It also reported comparable discontinuation rates between active and placebo groups.⁷ These results combined standalone cagrilintide and combination evidence, so they do not provide a purely standalone safety estimate.⁷

An earlier review of amylin analogues reported that nausea appeared more often with cagrilintide than with pramlintide in early trials.¹ That was a review-level comparison, not a direct finding from one head-to-head trial described in the collected abstract.¹ Meanwhile, the large REDEFINE 1 abstract detailed gastrointestinal events mainly for the combination group.² Those combination figures should not be assigned to cagrilintide alone.² Standalone trials monitored safety.² The available summaries do not settle every long-term or uncommon risk.²

Kidney and liver studies asked a different question

Two small human studies examined cagrilintide after one administration in adults grouped by kidney or liver function.⁴ The kidney study included 33 participants, while the liver study included 32.⁴ Researchers compared overall exposure and other pharmacokinetic measures across normal, mild, moderate, and severe impairment groups.⁴

They found similar exposure across groups, without a consistent pattern linked to impairment.⁴ No serious treatment-emergent adverse events, withdrawals caused by such events, or deaths were reported.⁴ The researchers also saw no rise in event counts as impairment increased.⁴ These short-term observations came from very small samples and a single-administration design.⁴ They cannot show whether long-term outcomes differ in people with kidney or liver disease.⁴

Laboratory and animal findings explain, but do not prove

Structural laboratory work mapped cagrilintide bound to active amylin receptors and the calcitonin receptor.⁵ The researchers found an amylin-like binding mode with distinct receptor-complex dynamics.⁵ This helps explain biological plausibility, but receptor structures do not measure weight or safety in people.⁵

Another laboratory study exposed mouse muscle cells and primary human muscle cells to cagrilintide.⁶ It reported temporary reductions in measures of mitochondrial respiration after 48 hours, which resolved by day five.⁶ These were cell-culture findings, not observations from treated people.⁶

Animal research also identified brainstem cell populations linked to cagrilintide’s effects in rats.⁸ Knocking down a specific signal blocked cagrilintide’s effects on energy balance in those animals.⁸ Cross-species mapping found related cells, but the intervention test itself was in rats.⁸ It cannot establish the same causal pathway or outcome in humans.⁸

Combination trials answer another clinical question

Several phase 3 studies tested cagrilintide together with semaglutide.⁹ One enrolled adults with overweight or obesity and type 2 diabetes, comparing the combination with placebo.⁹ Other studies examined early type 2 diabetes, basal-insulin treatment, or adults in Japan and Taiwan.¹⁰ These populations and background treatments were different, which matters when interpreting results.¹⁰

REIMAGINE 2 is especially useful because it included a cagrilintide-alone group of 152 adults with type 2 diabetes.¹¹ Participants were already receiving metformin, with or without another glucose-lowering medicine.¹¹ The study’s primary comparison was still the combination against semaglutide, not standalone cagrilintide against placebo.¹¹ Its abstract reports adverse events for the cagrilintide group but not a standalone glucose or weight effect estimate.¹¹

Semaglutide appears below only as a neutral related catalog reference.

What researchers are still testing

A registered clinical study in people with alcohol-related liver disease includes cagrilintide-alone and combination groups.¹² The registry summary says researchers will examine liver damage and alcohol use over about 39 weeks.¹² A registered design indicates planned research; it does not provide a completed outcome.¹² It also concerns a specific disease population, not adults seeking general weight management.¹²

The wider literature also includes narrative reviews and network meta-analyses.¹ These can organize results across interventions. Indirect comparisons, though, cannot replace direct randomized comparisons.³ The clearest conclusion is narrow.² Human studies have tested standalone cagrilintide mainly for body-weight change and safety in selected adults.² Smaller studies tested drug handling in kidney or liver impairment.⁴ Studies of cells, receptor structures, and animals offer hypotheses rather than clinical proof.⁵

Bottom line

Cagrilintide on its own has a human evidence base.² It is narrower than the combination literature may suggest.² Randomized trials included standalone groups.² They focused mainly on body-weight change and safety in adults with overweight or obesity.² A four-trial meta-analysis found greater average weight reduction than placebo.³ It reported no significant glycemic effect for cagrilintide alone.³ Small studies separately examined drug exposure across kidney and liver function groups after one administration.⁴ Laboratory and animal work explored receptors, muscle-cell responses, and brain pathways without proving human outcomes.⁵ For Filipino readers, the safest interpretation is simple: match every claim to the population, comparison, and study type that produced it.¹⁰

This article is educational research context, not medical advice. Catalog links are neutral references and do not imply a treatment or human-use recommendation.

Frequently asked questions

Has cagrilintide been tested without semaglutide?

Yes. Large randomized studies included groups assigned cagrilintide alone.² REDEFINE 1 had 302 adults in its standalone group.¹¹ REIMAGINE 2 had 152 adults with type 2 diabetes in a cagrilintide group.¹¹ Both trials also studied combinations, so their primary questions were broader than standalone use.²

What outcome has been studied most directly?

Body-weight change is the clearest recurring standalone clinical outcome.² A meta-analysis found a pooled difference of minus 6.08 percentage points versus placebo.³ This is an average trial comparison, not an individual forecast.³ The trials enrolled selected adults with overweight or obesity, sometimes with related conditions.²

Did standalone cagrilintide improve blood sugar?

The pooled analysis found no statistically significant glycemic effect for cagrilintide alone.³ That conclusion belongs to the trials included in that review.³ Combination trials in type 2 diabetes reported glucose-related outcomes.⁹ Those results reflect cagrilintide plus semaglutide and cannot be reassigned to cagrilintide alone.⁹

What did studies find about side effects?

Trials monitored adverse events, and reviews highlighted gastrointestinal effects, including nausea.¹ A pooled analysis reported more overall events with active cagrilintide-based treatment, while discontinuation rates were comparable with placebo.⁷ Because that analysis included combination evidence, it does not establish a clean standalone frequency for every event.⁷

Have people with kidney or liver impairment been studied?

Yes, in two small studies after one administration.⁴ Researchers included 33 people in the kidney study and 32 in the liver study.⁴ Exposure appeared similar across impairment groups, but the small samples and short design limit conclusions about longer-term outcomes.⁴

Do laboratory findings show how cagrilintide works in people?

They offer possible explanations, not clinical proof.⁵ Structural studies mapped receptor binding, while cell experiments measured temporary mitochondrial changes.⁶ Rat experiments identified a brainstem pathway involved in energy-balance effects.⁸ None of these designs directly establishes a health outcome in Filipino or other human populations.⁸

Is evidence from the combination relevant to cagrilintide alone?

It helps explain the direction of research, but it cannot assign an effect to one component.⁹ Combination trials tested two agents together in set populations and settings.¹⁰ Claims about cagrilintide itself need evidence from a standalone arm or a direct standalone comparison.¹¹

Sources

Footnotes

1. Amylin analogs for the treatment of obesity without diabetes: present and future.. Narrative review of amylin analogues and early clinical trials in adults without diabetes. A review summarizes underlying studies and does not replace direct trial reports. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹

2. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.. Randomized, double-blind, phase 3a human trial in adults with obesity or overweight plus a related condition. The primary comparisons and numerical results in the abstract center on the cagrilintide-semaglutide combination. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵ ↩¹⁶ ↩¹⁷ ↩¹⁸ ↩¹⁹ ↩²⁰ ↩²¹ ↩²² ↩²³ ↩²⁴ ↩²⁵ ↩²⁶ ↩²⁷ ↩²⁸

3. Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.. Systematic review and random-effects meta-analysis of randomized trials in 5,023 adults with overweight or obesity. The pooled evidence base was small and included both standalone and combination interventions. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵ ↩¹⁶ ↩¹⁷ ↩¹⁸

4. Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.. Human pharmacokinetic studies involving 33 participants grouped by kidney function and 32 grouped by liver function. Small samples and a single-administration design cannot establish longer-term outcomes. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴

5. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.. Laboratory structural and receptor-dynamics study. Receptor structures do not demonstrate clinical outcomes in humans. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

6. Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro.. Laboratory study in mouse muscle cells with selected findings repeated in primary human muscle cells. These were cell experiments, not observations from treated people. ↩ ↩² ↩³ ↩⁴ ↩⁵

7. Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.. Pooled analysis of randomized cagrilintide-alone and cagrilintide-semaglutide trials. The summary does not provide a purely standalone estimate for every adverse event. ↩ ↩² ↩³ ↩⁴ ↩⁵

8. A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.. Transcriptomic mapping across rats, mice, macaques, and humans, with causal intervention experiments in rats. The causal findings in rats do not establish the same pathway or outcomes in humans. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

9. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.. Randomized, double-blind, phase 3a combination trial in 1,206 adults. Combination results cannot be attributed to cagrilintide alone. ↩ ↩² ↩³ ↩⁴ ↩⁵

10. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.. Randomized, double-blind, active-controlled phase 3a trial in an East Asian population. Its population and combination design limit inference about standalone cagrilintide or Filipino readers. ↩ ↩² ↩³ ↩⁴

11. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.. Randomized, double-blind, phase 3 trial in adults receiving metformin with or without an SGLT2 inhibitor. The abstract does not provide a standalone glucose or weight effect estimate for cagrilintide. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

12. Effects of NNC0194-0499 Alone and in Combination With Semaglutide, of Semaglutide Alone, and of Cagrilintide Alone and in Combination With Semaglutide on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease. Clinical trial registry record for a planned 39-week human study. A registry description provides a design, not completed results. ↩ ↩² ↩³ ↩⁴